Shenyang Xingqi Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of ophthalmic drugs in the People's Republic of China. The company offers myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory and anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs, intraocular rinsing fluids, pupil dilatant and ciliary muscle paralyzers, anti-fatigue medicines, dry eye treatment medicines, mydriatics and cycloplegia drugs, miotics and anti-glaucoma drugs, and intraoperative intraocular irrigation fluids. It also engages in technology development, technical advice, eye hospital, and research and experimental development activities. Shenyang Xingqi Pharmaceutical Co.,Ltd. was founded in 1977 and is based in Shenyang, the People's Republic of China.
Research context
Shenyang Xingqi Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Shenyang Xingqi Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 2.5% below its 200 day moving average.
From a valuation standpoint, the stock is 40.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.5.
Shenyang Xingqi Pharmaceutical Co., Ltd's total revenue rose by 46.5% to $233M since the same quarter in the previous year.
Its net income has increased by 68.3% to $38M since the same quarter in the previous year.
Finally, its free cash flow grew by 420.3% to $21M since the same quarter in the previous year.
Based on the above factors, Shenyang Xingqi Pharmaceutical Co., Ltd gets an overall score of 3/5.